(Date:12/14/2009)... JUPITER, Fla., Dec. 14 Dyadic International, ... it has extended its collaboration with The Scripps ... with Scripps to re-annotate the genome of Dyadic,s ... agreement is a continuation of the successful relationship ... 2006 when Dyadic engaged Scripps to annotate the ...
(Date:12/14/2009)... CARLOS, Calif., Dec. 14 Nektar Therapeutics ... Winger has been appointed to serve on its ... biopharmaceutical industry leader with over 35 years of ... ,, "Dennis brings to Nektar extensive industry perspective ... said Howard W. Robin, President and CEO of ...
(Date:12/11/2009)... -- Dendreon Corporation (Nasdaq: DNDN ) announced ... public offering have exercised in full their option ... stock at the public offering price of $24.75 ... increases the size of the offering to an ... Dendreon expects to receive net proceeds from the ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer therapeutics company, ... the,US, the Tulane Cancer Center, New Orleans, ... clinical study of Alpharadin in men with,castration-resistant ... has metastasized to the skeleton. , ... SYMptomatic Prostate CAncer) study is a,double-blind, randomized, ...
Breaking Biology Technology:Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4... ARLINGTON, Va., March 17 The 2008 Life ... Boston Waterfront Hotel on June,3, 2008 at a ... Leading market research firm,BioInformatics, LLC ( http://www.gene2drug.com ) ... this year,s awards., The annual awards honor ...
... Inc., a developer of advanced medical devices for ... that it has enrolled its,first patient in the ... prospective,multi-centered U.S. registry study of the company,s OmniWave(TM),Endovascular ... acute deep vein thrombosis (DVT). All patients enrolled ...
... 17 Alimera Sciences,and pSivida Ltd (Nasdaq: ... that,they have amended their license and collaboration agreement ... treatment for,diabetic macular edema (DME), and other Medidur ... profits of Medidur FA from 50 to 80,percent ...
Other Biology Technology:Life Science Industry Awards to Be Announced June 3, 2008 in Boston 2Life Science Industry Awards to Be Announced June 3, 2008 in Boston 3First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies' OmniWave(TM) Endovascular System 2Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 2Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 3Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 4Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
... The JASCO Model AS-2055 and AS-2057 are ... productivity and,the highest possible level of precision. ... 384 well positions (microplate) for,laboratory automation and ... for 84 micro-vials or the standard rack ...
... ImmEdge Pen, a hydrophobic barrier pen for ... for use with frozen or paraffin-embedded tissue ... Pen provides a heat-stable, water-repellent barrier that ... sections, prevents mixing of reagents when differentially ...
Mouse monoclonal antibody raised against a partial recombinant VEGFB. NCBI Entrez Gene ID = VEGFB...
Biology Products:Biology NavigationMedical Navigation